Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of SAGE-324 in essential tremor
NCT05366751Phase 3Terminated
- Sponsor
- Sage Therapeutics
- Start
- Jun 2022
- Primary completion
- Sep 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of sage-324 in essential tremor (ET), sponsored by Sage Therapeutics. Started Jun 2022; status: terminated.
02
Drugs
sage-324
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT05366751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366751.